表紙
市場調查報告書

肌肉萎縮症:開發中產品分析

Muscle Atrophy - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 619902
出版日期 內容資訊 英文 37 Pages
訂單完成後即時交付
價格
Back to Top
肌肉萎縮症:開發中產品分析 Muscle Atrophy - Pipeline Review, H2 2019
出版日期: 2019年11月18日內容資訊: 英文 37 Pages
簡介

所謂肌肉萎縮症,是肌肉組織減少的疾病之一。主要的症狀,是肌肉的損耗和弱化、疼痛、運動能力的喪失,面部無力,手臂、腳的發麻和刺痛等。主要的病因,有老齡化和神經疾病,中風,運動神經障礙,肌肉萎縮症,關節炎等。主要的治療方法,有運動療法和飲食習慣改善,外科手術等。

本報告提供全球各國的肌肉萎縮症的開發中產品的開發情形相關分析,開發中產品的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業的簡介,主要藥物概要,最新的產業趨勢 (臨床實驗調查中斷中/已中止的產品等) 等。

目錄

  • 簡介
    • 分析範圍
  • 肌肉萎縮症概要
  • 肌肉萎縮症:治療藥的開發
    • 開發平台概要
    • 各企業的開發平台趨勢
    • 各大學、研究機關的開發平台趨勢
    • 企業開發中的產品
    • 在大學、研究機關開發中的產品
  • 肌肉萎縮症:治療藥的評估
    • 各標的
    • 各作用機制
    • 各給藥途徑
    • 各分子類型
  • 肌肉萎縮症:開發治療藥的企業
    • Escape Therapeutics Inc
    • K-Stemcell Co Ltd
    • Milo Biotechnology LLC
    • 鹽野義製藥
    • Spherium Biomed SL
    • Teijin製藥
  • 肌肉萎縮症:藥物的簡介
    • AAV9-forisutachin
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • EMMY-105
    • EMMY-106
    • FibroStem
    • JP4-039
    • 肌肉萎縮症用、HSD11B1阻礙小分子
    • SP-15028
    • Parry-Romberg病、血栓血管炎的幹細胞治療
    • TEISARM-2
  • 肌肉萎縮症:暫停的計劃
  • 肌肉萎縮症:開發中止的產品
  • 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11499IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscle Atrophy - Pipeline Review, H2 2019, provides an overview of the Muscle Atrophy (Musculoskeletal Disorders) pipeline landscape.

Muscle atrophy is the wasting or loss of muscle tissue. Symptoms of muscle atrophy include muscle damage, pain, weak muscles, loss of movement, facial weakness and numbness or tingling in arms or legs. Causes include aging, nerve diseases, stroke, motor neuropathy, muscular dystrophy and arthritis. Treatment includes exercise, dietary changes and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Muscle Atrophy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Muscle Atrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscle Atrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscle Atrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical, Discovery and Unknown stages are 7, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Muscle Atrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Muscle Atrophy (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Muscle Atrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Muscle Atrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Muscle Atrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Muscle Atrophy (Musculoskeletal Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Muscle Atrophy (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Muscle Atrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Muscle Atrophy - Overview
  • Muscle Atrophy - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Muscle Atrophy - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Muscle Atrophy - Companies Involved in Therapeutics Development
    • Avidity Biosciences LLC
    • Emmyon Inc
    • Hana Pharm Co Ltd
    • Helixmith Co Ltd
    • K-Stemcell Co Ltd
    • Milo Biotechnology LLC
    • Shionogi & Co Ltd
    • Teijin Pharma Ltd
  • Muscle Atrophy - Drug Profiles
    • AAV9-Follistatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense Oligonucleotides for Muscle Atrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EMMY-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EMMY-106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Muscular Atrophy, Sarcopenia and Traumatic Nerve Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HNP-6005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JP-4039 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit HSD11B1 for Muscle Atrophy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Parry-Romberg disease and Thromboangiitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TEISARM-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Muscle Atrophy - Dormant Projects
  • Muscle Atrophy - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Muscle Atrophy, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Muscle Atrophy - Pipeline by Avidity Biosciences LLC, H2 2019
  • Muscle Atrophy - Pipeline by Emmyon Inc, H2 2019
  • Muscle Atrophy - Pipeline by Hana Pharm Co Ltd, H2 2019
  • Muscle Atrophy - Pipeline by Helixmith Co Ltd, H2 2019
  • Muscle Atrophy - Pipeline by K-Stemcell Co Ltd, H2 2019
  • Muscle Atrophy - Pipeline by Milo Biotechnology LLC, H2 2019
  • Muscle Atrophy - Pipeline by Shionogi & Co Ltd, H2 2019
  • Muscle Atrophy - Pipeline by Teijin Pharma Ltd, H2 2019
  • Muscle Atrophy - Dormant Projects, H2 2019
  • Muscle Atrophy - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Muscle Atrophy, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top